DCM
EIGR

DAFNA Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

DAFNA Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,199
Closed -$284K – 82
2017
Q2 		$284K Hold
1,199
– – 0.2% 62
2017
Q1 		$412K Sell
1,199
-141
-11% -$48.6K 0.35% 56
2016
Q4 		$468K Sell
1,340
-1,660
-55% -$608K 0.41% 54
2016
Q3 		$1.21M Buy
+3,000
New +$1.53M 0.84% 40

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DAFNA Capital Management's EIGR Position: Q3 2017 in Review

DAFNA Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2017, closing a stake of 1,199 shares — an estimated $284K sold.

DAFNA Capital Management first reported a position in EIGR in Q3 2016 and held it in 4 quarters. The position peaked at $1.21M in Q3 2016. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

  • DAFNA Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 1,199 Eiger BioPharmaceuticals, Inc. shares in Q3 2017, an estimated $284K.
  • DAFNA Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2016 and held it in 4 quarters.
  • DAFNA Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $1.21M in Q3 2016.
  • 33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.